Compare BIO & CENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIO | CENX |
|---|---|---|
| Founded | 1952 | 1995 |
| Country | United States | United States |
| Employees | 7450 | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Aluminum |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 6.1B |
| IPO Year | N/A | 2004 |
| Metric | BIO | CENX |
|---|---|---|
| Price | $254.19 | $59.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $339.75 | $65.67 |
| AVG Volume (30 Days) | 241.5K | ★ 1.4M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.42 |
| Revenue | N/A | ★ $1,893,200,000.00 |
| Revenue This Year | $2.74 | $20.77 |
| Revenue Next Year | $3.20 | $14.58 |
| P/E Ratio | ★ $9.72 | $141.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $211.43 | $14.77 |
| 52 Week High | $343.12 | $68.69 |
| Indicator | BIO | CENX |
|---|---|---|
| Relative Strength Index (RSI) | 33.87 | 47.56 |
| Support Level | $246.01 | $57.48 |
| Resistance Level | $289.61 | $68.69 |
| Average True Range (ATR) | 10.43 | 2.83 |
| MACD | -3.76 | -0.91 |
| Stochastic Oscillator | 17.46 | 14.11 |
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Century Aluminum Co produces primary aluminum standard grade and value-added products. The firm operates smelter facilities in the United States and Iceland. The majority of revenue is generated from Glencore, which agreed to purchase nearly all of Century Aluminum's North American production. The company produces high purity aluminum, standard-grade aluminum sow and tee bars, and value-added billet and foundry products. The company also owns a carbon anode production facility in the Netherlands.